Welcome to our dedicated page for Delcath Sys news (Ticker: DCTH), a resource for investors and traders seeking the latest updates and insights on Delcath Sys stock.
Delcath Systems, Inc. develops interventional oncology products for primary and metastatic liver cancers. Its core products include HEPZATO KIT, a melphalan and Hepatic Delivery System combination product approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma, and CHEMOSAT Hepatic Delivery System for Melphalan used in percutaneous hepatic perfusion.
Recurring news covers quarterly operating results, HEPZATO KIT and CHEMOSAT revenue, clinical publications from studies such as FOCUS and CHOPIN, presentations at oncology and interventional radiology meetings, guideline recognition, and studies of melphalan-based percutaneous hepatic perfusion in liver-dominant cancers. Company updates also address FDA-approved product status, European clinical practice references, and capital actions such as common-stock repurchases.
Delcath Systems, Inc. (NASDAQ: DCTH) appointed Gerard Michel as the new CEO effective October 1, 2020, succeeding John Purpura, who becomes COO. Michel, with over 30 years in the pharmaceutical industry, previously served at Vericel Corporation, contributing to its growth into a commercial leader. He aims to advance Delcath's Melphalan/HDS product for treating metastatic ocular melanoma, targeting a New Drug Application resubmission in mid-2021. The company also granted Michel stock options to align his interests with shareholder value.
Delcath Systems, focused on liver-directed treatments, announced its participation in two investor conferences. The first is the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 4:30 PM EDT, featuring a live webcast. The second event is the Oppenheimer Fall Healthcare Life Science & Med Tech Summit on September 23, 2020. Virtual one-on-one meetings with management can be scheduled. Delcath's investigational product, Melphalan Hydrochloride for Injection, targets liver cancer treatment and has not yet received FDA approval.
Delcath Systems, a company specializing in interventional oncology for liver cancers, will present at the LD Micro 500 Virtual Conference on September 1, 2020, at 3:00 PM ET. A live webcast of this presentation will be publicly accessible and archived for 90 days. Delcath is known for its innovative treatment Melphalan Hydrochloride, designed for high-dose localized chemotherapy, and is conducting Phase 3 clinical trials for various liver cancers, including intrahepatic cholangiocarcinoma. The company’s system is marketed in Europe under the name Delcath CHEMOSAT.
Delcath Systems (NASDAQ: DCTH) reported its Q2 2020 financial results, highlighting a net loss of $4.3 million, improving from a $6.0 million loss the previous year. Product revenue rose to $262,000, up from $221,000. The company completed a $22 million public offering aimed at funding a Phase 3 trial for Melphalan/HDS in metastatic ocular melanoma (mOM). Delcath also emphasized plans for NDA submission by mid-2021 and further clinical studies in liver-dominant cancers, with cash resources sufficient until mid-2021.
Delcath Systems (NASDAQ: DCTH) announced that John Purpura, interim CEO, will present at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 9 a.m. ET. A webcast of the presentation will be available for viewing. The company, renowned for its liver-directed treatments for cancers, is also engaging in one-on-one investor meetings. Delcath’s investigational product, Melphalan Hydrochloride for Injection, aims to deliver high-dose chemotherapy to the liver while minimizing systemic exposure. The system has not yet received FDA approval but is marketed in Europe as CHEMOSAT.